Sign up
Pharma Capital

Verona Pharma's chief medical officer to quit at the end of the month

The search is already underway for Kenneth Newman's replacement
doctor looking at lung x-ray
The company is developing a drug for chronic obstructive pulmonary disease

Respiratory specialist Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said its chief medical officer, Kenneth Newman, is quitting the company at the end of the month to “pursue other opportunities”.

The search is already underway for his replacement.

WATCH: Can Verona Pharma hit the dizzy heights of 5p again?

Chief executive Jan-Anders Karlsson thanked Newman for his “outstanding service” over the past three years.

This included the acceleration into phase IIb clinical trials of Verona’s chronic obstructive pulmonary disease drug candidate.

In total, Newman oversaw seven clinical trials and played an instrumental role in establishing the drug developer’s US presence.


Register here to be notified of future VRP Company articles
View full VRP profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.